Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Newark Beth Israel Medical Center

Status and phase: Unknown; Phase 4

Conditions: Acute Coronary Syndrome; Smoking

Treatments: Drug: control; Drug: Varenicline 100 mg by mouth twice daily

Study type: Interventional

Funder types: Other

Identifiers

NCT01170338

2008.68

Details and patient eligibility

About

Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• active smokers presenting to hospital with an acute coronary syndrome

Exclusion criteria

• patients with an acute coronary syndrome who are not active smokers

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups, including a placebo group

active Chantix

Experimental group

Description:

active drug to help smoking cessation

Treatment:

Drug: Varenicline 100 mg by mouth twice daily

sugar pill

Placebo Comparator group

Treatment:

Drug: control